Comments on the pathogenesis and medical treatment of central giant cell granulomas
Authors:
- Joseph A. RegeziJRJoseph A. Regezi
- M.ANthony PogrelMPM.ANthony Pogrel
- 1 January 2004
- journal article
- Published by Elsevier in Journal of Oral and Maxillofacial Surgery
- Vol. 62 (1) , 116-118
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritisArthritis & Rheumatism, 2002
- Adenosine triphosphate stimulates human osteoclast activity via upregulation of osteoblast-expressed receptor activator of nuclear factor-κB ligandBone, 2002
- Phenotypic characterization of mononuclear and multinucleated cells of giant cell reparative granuloma of small bonesThe Journal of Pathology, 2002
- Novel approaches to the management of bone metastases in patients with breast cancerSeminars in Oncology, 2002
- Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/ protein and vascular endothelial growth factorSeminars in Oncology, 2002
- RANK (Receptor Activator of Nuclear Factor kappa B) and RANK Ligand Are Expressed in Giant Cell Tumors of BoneAmerican Journal of Clinical Pathology, 2002
- Human Osteoclast Cathepsin K Is Processed Intracellularly Prior to Attachment and Bone ResorptionJournal of Bone and Mineral Research, 2001
- Regulation of osteoclastogenesis and RANK expression by TGF‐β1Journal of Cellular Biochemistry, 2001
- Expression of Osteoclast Differentiation Signals by Stromal Elements of Giant Cell TumorsJournal of Bone and Mineral Research, 2000
- Immunohistochemical expression of p53, MDM2, Ki‐67 and PCNA in central giant cell granuloma and giant cell tumorJournal of Oral Pathology & Medicine, 1999